Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Home
Search
Quick Search
Advanced
Fulltext
Browse
Collections
Persons
My eDoc
Session History
Login
Name:
Password:
Documentation
Help
Support Wiki
Direct access to
document ID:


          Institute: MPI für molekulare Genetik     Collection: Department of Vertebrate Genomics     Display Documents



  history
ID: 547481.0, MPI für molekulare Genetik / Department of Vertebrate Genomics
Blocking TLR2 in vivo protects against accumulation of inflammatory cells and neuronal injury in experimental stroke.
Authors:Ziegler, G.; Freyer, D.; Harhausen, D.; Khojasteh, U.; Nietfeld, W.; Trendelenburg, G.
Language:English
Copyright:© 2011 International Society for Cerebral Blood Flow & Metabolism
Audience:Popular
Abstract / Description:Reduced infarct volume in TLR2-knockout mice compared with C57Bl/6 wild-type mice has recently been shown in experimental stroke and confirmed in this study. We now also show a significant decrease of CD11b-positive cell counts and decreased neuronal death in the ischemic hemispheres of TLR2-deficient mice compared with C57Bl/6wt mice 2 days after transient focal cerebral ischemia. To examine the potential benefit of intravascular TLR2 inhibition, C57Bl/6wt mice were treated intraarterially with TLR2-blocking anti-TLR2 antibody (clone T2.5) after 45 minutes of cerebral ischemia and compared with control antibody (isotype) treated wild-type mice. Whereas T2.5-treated mice had no reduction in infarct volumes at 48 hours after reperfusion, they did have decreased numbers of CD11b-positive inflammatory cells and decreased neuronal death compared with isotype-treated control mice. Comparison of the isotype antibody treatment to control (saline) treatment showed no effects on infarct volumes or neuronal survival. However, mice treated with the control isotype antibody had increased numbers of CD11b-positive inflammatory cells compared with saline-treated animals. Thus, antibody treatment itself (i.e., control isotype antibody, but potentially of any antibody) may have adverse effects and limit therapeutic benefit of anti-TLR2-antibody therapy. We conclude that TLR2 mediates leukocyte and microglial infiltration and neuronal death, which can be attenuated by TLR2 inhibition. The TLR2 inhibition in vivo improves neuronal survival and may represent a future stroke therapy.Journal of Cerebral Blood Flow & Metabolism advance online publication, 15 September 2010; doi:10.1038/jcbfm.2010.161.
Free Keywords:cerebral ischemia;
MCAO;
neuroprotection;
stroke;
TLR2;
toll-like receptor
Comment of the Author/Creator:Correspondence: Dr G Trendelenburg, Experimentelle Neurologie, Neurologische Klinik und Poliklinik, Charité-Universitätsmedizin Berlin, CCM Charitéplatz 1, Berlin 10117, Germany.
E-mail: george.trendelenburg@charite.de
Document Type:Article
Communicated by:Hans Lehrach
Affiliations:MPI für molekulare Genetik
External Affiliations:1.Experimentelle Neurologie, Charité-Universitätsmedizin, Berlin, Germany;
2.Center for Stroke Research Berlin, Charité Universitätsmedizin, Berlin, Germany;
3.Klinik und Poliklinik für Neurologie, Charité Universitätsmedizin, Berlin, Germany.
Identifiers:ISSN:10.1038/jcbfm.2010.161 [ID No:1]
URL:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=... [ID No:2]
DOI:0271-678X [ID No:3]
Full Text:
Sorry, no privileges
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.